Cure8 research brief
The paper identifies a new metabolic cell-death pathway (HIF-1α–driven lactylation leading to ferroptosis) that may contribute to colonic injury in ulcerative colitis and presents quercetin as a compound that blocks this pathway in preclinical models.
If validated in humans, targeting this axis could point to new therapies.
Researchers studying IBD pathogenesis, scientists working on metabolism and cell-death pathways (ferroptosis), and clinicians interested in emerging mechanistic targets for ulcerative colitis.
The paper uses bioinformatics, cell models, and in vivo experiments to show that HIF-1α drives glycolysis and lactate accumulation, which increases protein lactylation and promotes ferroptosis (an iron-dependent form of cell death) in colonic epithelial models of UC.
Reducing lactate production or knocking down HIF-1α lowered markers of ferroptosis, lipid peroxidation, and ROS. The authors screened compounds and present quercetin as a candidate that binds HIF-1α and inhibited this pathway in their models, with reported benefit in experimental colitis. This is preclinical mechanistic research.
It suggests a potential metabolic pathway that could be targeted but does not provide clinical evidence that quercetin or HIF-1α inhibition is effective or safe in people with UC.
This is an abstract-level report of basic-science work (bioinformatics, cell culture, and animal experiments). It does not report human clinical data. Quercetin is a flavonoid found in foods and supplements; the study's findings do not establish clinical benefit or safety in people with UC.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The paper identifies a metabolic pathway (HIF-1α–driven lactylation leading to ferroptosis) that may contribute to epithelial injury in ulcerative colitis and proposes quercetin as a candidate inhibitor—potentially...
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
The study identifies a cellular mechanism by which arctigenin reduced inflammatory macrophage death and improved colitis in mice, suggesting a potential new target (macrophage FAO → GSDMD) for therapies or...
